Health Technology Assessment Under Scrutiny - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Health Technology Assessment Under Scrutiny
The rising cost of healthcare has complicated the introduction of new, innovative drugs and other medical technologies. While the medical impact of these healthcare advances cannot be denied, governments and healthcare policy makers have found it difficult to sustain the funding of these expensive treatments.

Pharmaceutical Technology Europe
Volume 23, Issue 9


1. C.S Goodman, "HTA 101: Introduction to Health Technology Assessment" (National Information Center on Health Services Research and Healthcare Technology, US National Library of Medicine, National Institutes of Health, January, 2004),, accessed 12 August 2011.

2. H. Redwood, Why Ration Health Care? (CIVITAS, London, UK 2000).

3. Charles River Associates, A Comparative Analysis Of The Role And Impact Of Health Technology Assessment (2011, MA, USA).

4. C. Sorenson, M. Drummond and P. Kanavos, The Role Of Health Technology Assessment In The European Union. The European Observatory on Health Systems and Policies (MPG Books, Cornwall, UK, 2008).

5. Tufts Center for the Study of Drug Development, "Drug Developers Are Aggressively Changing the Way They Do R&D", Press Release (MA, USA, 2011).

6. K. Grogan, "Uproar over NICE rejection of Novartis MS pill", Pharma Times (5 August 2011).

7. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), "The German IQWiG — It's Not NICE Benefit Assessment in Germany — New Sense or Nuisance?", accessed 8 August 2011.

8. International Network of Agencies for Health Technology Assessment (INAHTA), "IQWIG — Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen", accessed 8 August 2011.

9. A. Jouan, Le Figaro (27 March 2011)., accessed 12 August 2011.

10. Haute Autorité de Santé, "Le NICE, l'IQWIG et la HAS concluent un accord de coopération", Press Release, (France, 13 April 2006).

11. Haute Autorité de Santé, "Mise au point de la Haute Autorité de Santé sur Mediator", Press Release, (France, 1 December 2010).

12. A. Braillon, The Lancet, 377 (9782), 2003–2004 (2011).

13. EFPIA, "New Study on HTA Processes Highlights Areas for Improvement to Accelerate Patients' Access to Innovative Medicines", Press Release (Belgium, 13 July 2011).London, UK


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here